These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 15643463

  • 1. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K, Reikvam A.
    Tidsskr Nor Laegeforen; 2005 Jan 06; 125(1):38-40. PubMed ID: 15643463
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 06; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Oct 06; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 4. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 06; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 06; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 6. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Eur Heart J; 2005 Nov 06; 26(22):2361-7. PubMed ID: 16105846
    [Abstract] [Full Text] [Related]

  • 7. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 21; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 9. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D.
    Can J Cardiol; 2005 May 15; 21(7):569-75. PubMed ID: 15940354
    [Abstract] [Full Text] [Related]

  • 10. ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure.
    Gold JA, Rahko PS.
    WMJ; 2004 May 15; 103(1):71-2. PubMed ID: 15101473
    [No Abstract] [Full Text] [Related]

  • 11. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.
    Am J Kidney Dis; 2005 Dec 15; 46(6):1080-7. PubMed ID: 16310574
    [Abstract] [Full Text] [Related]

  • 12. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G, Preblick R, Hill J, Plauschinat CA, Yaskin J.
    Congest Heart Fail; 2009 Dec 15; 15(4):170-5. PubMed ID: 19627290
    [Abstract] [Full Text] [Related]

  • 13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 15; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 14. [Current aspects of ACE inhibitor therapy from the cardiologic viewpoint].
    Klein W, Eber B, Gasser R, Stoschitzky K, Schumacher M, Fruhwald FM, Zweiker R.
    Wien Med Wochenschr; 1996 Sep 15; 146(11):221-4. PubMed ID: 8928518
    [Abstract] [Full Text] [Related]

  • 15. Renin-angiotensin system modulation: the weight of evidence.
    Brown B, Hall AS.
    Am J Hypertens; 2005 Sep 15; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [Abstract] [Full Text] [Related]

  • 16. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 15; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 15; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 18. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 15; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 19. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

  • 20. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I, Rubonivich S, Azaz-Livshits T.
    Isr Med Assoc J; 2008 Mar 15; 10(3):214-8. PubMed ID: 18494235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.